Epidemiology and evaluation of chronic pelvic pain syndrome in men

Schaeffer, Anthony J.

doi:10.1016/j.ijantimicag.2007.08.027

Cited by 63 publications

(50 citation statements)

References 39 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Patients with CP/CPPS have variant etiology that largely does not involve previous infection of or direct injury to the prostate [1][2][3] . Despite this fact, published models of CP/CPPS have incorporated direct or indirect inflammation of the prostate to induce hypersensitivity of the perigenital region and/or mast cell activation.…”

Section: Discussionmentioning

confidence: 99%

“…These syndromes are often comorbid and share many characteristics in that they have no associated pathology or identified underlying etiology, although dysfunction within the immune system, central nervous system, and peripheral nervous system has been shown to contribute towards the maintenance and progression of these disorders [1][2][3] . Patients with chronic pelvic pain are more likely to present with symptoms of additional, non-pelvic-related functional pain disorders and mood disorders, including anxiety, depression, and panic disorder [4][5][6] , which has been associated with altered functioning of the hypothalamic-pituitary-adrenal (HPA) axis [7][8][9][10] .…”

Section: Introductionmentioning

confidence: 99%

“…Patients with CP/CPPS report pain in the perineum, rectum, prostate, penis, testicles, and/or abdomen 28 , experience a higher degree of psychological stress than control patients 29 , and commonly present with symptoms of or are diagnosed with comorbid chronic pelvic pain or mood disorders 5,[29][30][31] . Recurrent infection, leaky epithelium, neurogenic inflammation, and autoimmunity have all been surmised as potential underlying causes of CP/CPPS 2,32,33 , as well as mast cell activation and degranulation 34 . Expressed prostatic secretions from men with CP/ CPPS had increased mast cell tryptase and nerve growth factor (NGF) levels .…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Assessment of Perigenital Sensitivity and Prostatic Mast Cell Activation in a Mouse Model of Neonatal Maternal Separation

Fuentes

Pierce

O’Neil

et al. 2015

JoVE

View full text Add to dashboard Cite

Chronic prostatitis/chronic pelvic pain syndrome (CP/CPPS) has a lifetime prevalence of 14% and is the most common urological diagnosis for men under the age of 50, yet it is the least understood and studied chronic pelvic pain disorder. A significant subset of patients with chronic pelvic pain report having experienced early life stress or abuse, which can markedly affect the functioning and regulation of the hypothalamicpituitary-adrenal (HPA) axis. Mast cell activation, which has been shown to be increased in both urine and expressed prostatic secretions of CP/ CPPS patients, is partially regulated by downstream activation of the HPA axis. Neonatal maternal separation (NMS) has been used for over two decades to study the outcomes of early life stress in rodent models, including changes in the HPA axis and visceral sensitivity. Here we provide a detailed protocol for using NMS as a preclinical model of CP/CPPS in male C57BL/6 mice. We describe the methodology for performing NMS, assessing perigenital mechanical allodynia, and histological evidence of mast cell activation. We also provide evidence that early psychological stress can have long-lasting effects on the male urogenital system in mice. Video LinkThe video component of this article can be found at

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Assessment of Perigenital Sensitivity and Prostatic Mast Cell Activation in a Mouse Model of Neonatal Maternal Separation

Fuentes

Pierce

O’Neil

et al. 2015

JoVE

View full text Add to dashboard Cite

show abstract

“…CP/CPPS symptom distress and reduction in quality of life is comparable with congestive heart failure, Crohn's disease, diabetes mellitus and angina. 10 Suicidal thoughts are not uncommon in this population of men. 11 The distress, anguish and fear of not understanding their problem or having a clear treatment path is simply too much for some.…”

Section: The 'I' In Painmentioning

confidence: 91%

The inflammatory journey of a prostatitis patient

Monahan¹

2017

Trends Urology & Men Health

View full text Add to dashboard Cite

show abstract

“…Approximately 6%-12% of men suffer from CPPS; the disease affects millions worldwide [2]. It is similar to congestive heart failure, Crohn's disease, diabetes mellitus or angina [3] in lowering quality of life, and represents a serious economic burden on any health care system. Associated costs match those reported for peripheral neuropathy, low back pain, fibromyalgia, and rheumatoid arthritis [4].…”

Section: Introductionmentioning

confidence: 99%

467 Sono-electro-magnetic therapy for treating chronic pelvic pain syndrome in men: A randomized, placebo-controlled, double-blind trial

Mordasini¹,

Kessler²,

Weisstanner³

et al. 2014

European Urology Supplements

View full text Add to dashboard Cite

Objective: To assess the efficacy and safety of sono-electro-magnetic therapy compared to placebo in men with refractory CPPS. Patients and Methods: In a randomized, placebo-controlled, double-blind single center trial, we assessed the effect of sono-electro-magnetic therapy in men with treatment refractory CPPS. Sixty male patients were randomly assigned to treatment with either sono-electro-magnetic (n530) or placebo therapy (n530) for 12 weeks. The primary outcome was a change in the National Institutes of Health Chronic Prostatitis Symptom Index (NIH-CPSI) from baseline to 12 weeks. Results: The 12-week difference between sono-electro-magnetic and placebo therapy in changes of the NIH-CPSI total score was 23.1 points (95% CI 26.8 to 0.6, p50.11). In secondary comparisons of NIH-CPSI sub-scores, we found differences between groups most pronounced for the quality-of-life sub-score (difference at 12 weeks 21.6, 95% CI 22.8 to 20.4, p50.015). In stratified analyses, the benefit of sono-electro-magnetic therapy appeared more pronounced among patients who had a symptom duration of 12 months or less (difference in NIH-CPSI total score 28.3, 95% CI 214.5 to 2.6) than in patients with a longer symptom duration (20.8, 95% CI 24.6 to 3

show abstract

Epidemiology and evaluation of chronic pelvic pain syndrome in men

Cited by 63 publications

References 39 publications

Assessment of Perigenital Sensitivity and Prostatic Mast Cell Activation in a Mouse Model of Neonatal Maternal Separation

Assessment of Perigenital Sensitivity and Prostatic Mast Cell Activation in a Mouse Model of Neonatal Maternal Separation

The inflammatory journey of a prostatitis patient

467 Sono-electro-magnetic therapy for treating chronic pelvic pain syndrome in men: A randomized, placebo-controlled, double-blind trial

Contact Info

Product

Resources

About